Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

NCT05845268 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

102

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

COMBINATION_PRODUCT: Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
COMBINATION_PRODUCT: Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)

Sponsor

Beijing Friendship Hospital